ARPC1B and glioblastoma: This study further showed that GBM cell lines with high expression of ARPC1B and IFI16 were more sensitive to ceralasertib (AZD6738), an inhibitor of ATR. IFI16 was also upregulated in GBM cells treated with both Y15 (a small molecule inhibitor of activated focal adhesion kinase) and TMZ (Huang et al., 2014), a combination that decreases viability and tumor growth in GBM cells (Golubovskaya et al., 2013).